212 related articles for article (PubMed ID: 23299707)
1. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
Jiang X; Schnatz PF
Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
[No Abstract] [Full Text] [Related]
2. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
4. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
5. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
7. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
8. Denosumab in postmenopausal women with low bone mineral density.
Schwartzman J; Yazici Y
N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
[No Abstract] [Full Text] [Related]
9. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
[TBL] [Abstract][Full Text] [Related]
10. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
[TBL] [Abstract][Full Text] [Related]
11. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
12. Denosumab in postmenopausal women with low bone mineral density.
Rifkin WD
N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
[No Abstract] [Full Text] [Related]
13. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
14. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
17. Denosumab is an option for treatment of osteoporosis.
Simonelli C
Am Fam Physician; 2012 Dec; 86(11):992; author reply 994. PubMed ID: 23198660
[No Abstract] [Full Text] [Related]
18. Denosumab, osteoporosis, and prevention of fractures.
Kiechl S; Willeit J; Schett G
N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304
[No Abstract] [Full Text] [Related]
19. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
20. Multiple clinical vertebral fractures following denosumab discontinuation.
Anastasilakis AD; Makras P
Osteoporos Int; 2016 May; 27(5):1929-30. PubMed ID: 26694593
[No Abstract] [Full Text] [Related]
[Next] [New Search]